

CONCLUSION

TSHoma with acute stroke as an initial manifestation is uncommon. Interpretation of discordant TFT needs to be done and investigated carefully as TSHoma can be cured by surgical removal. In inoperable cases, medical therapy can control the disease well.

EP_A063

A CASE OF GIANT INVASIVE MACROPROLACTINOMA PRESENTING AS A NASOPHARYNGEAL MASS

https://doi.org/10.15605/jafes.038.S2.81

Li Sin Yeh, Chan Pei Lin, Florence Tan Hui Sieng

Endocrinology Unit, Medical Department, Sarawak General Hospital, Malaysia

INTRODUCTION/BACKGROUND

Giant prolactinomas are rare and can invade the surrounding structure. Invasion tends to involve the suprasellar and cavernous sinus region with a minority invading the base of the skull.

CASE

We describe a rare presentation of giant invasive prolactinoma masquerading as nasopharyngeal tumour.

A 33-year-old female presented to the ENT clinic with nasal congestion, blocked ear, progressive right-sided hearing loss for 4 months and epistaxis and headache for 2 weeks. Nasopharyngeal scope showed a large mass protruding from the nasopharynx into the nasal cavity. Biopsy taken reported a neuroendocrine tumour with diffusely positive immunohistochemistry for synaptophysin, chromogranin and vimentin. Ki67 was 10%. MRI of the brain showed a large nasopharyngeal mass (7.1 x 9.8 x 6.3 cm) with complete obliteration of the nasopharynx and erosion of the sphenoid bone and clivus. There was also extensive multidirectional invasion of the surrounding tissue. The patient was referred to the neurosurgery and oncology team. Further history found that the patient had oligomenorrhea for many years and became amenorrhoeic past 2 years. She denied galactorrhoea. Visual field testing showed left inferior quadrantanopia. Prolactin level was 625,740 uIU/mL. She was then referred to our endocrine service. Thyroid function and 8 am cortisol were normal. Further histopathology staining showed positivity for prolactin and ACTH. She was initiated on cabergoline 0.5 mg 3x/week. She developed a CSF leak after 2 weeks; after tumour debulking and leak repair, cabergoline dose was titrated to 0.5 mg daily. Prolactin reduced to 160727 uIU/mL and the tumour size decreased to 6.0 x 8.3 x 6.0 cm. Multidisciplinary team discussion decided on a trial of higher dose cabergoline (5.5

mg/week) prior to consideration for radiotherapy; however, the patient developed another CSF leak 1 month after dose titration, requiring another repair.

CONCLUSION

Invasive giant prolactinoma may rarely present with skull base invasion and intranasal extension masquerading as nasopharyngeal tumor. Careful clinical evaluation is important to diagnose this rare presentation to allow timely and appropriate management.

EP_A064

TSHoma: A CASE OF MISTAKEN IDENTITY

https://doi.org/10.15605/jafes.038.S2.82

Chong Li Ren Albert, Chan Pei Lin, Florence Tan Hui Sieng

Endocrinology Unit, Medical Department, Sarawak General Hospital, Malaysia

INTRODUCTION/BACKGROUND

TSH-secreting pituitary tumours are rare causes of hyperthyroidism. Its diagnosis is often delayed due to its uncommon presentation.

CASE

We report a case of TSHoma in a female initially misdiagnosed as Graves' disease.

A 36-year-old female was diagnosed with Graves' disease by a general practitioner since 2016 following symptoms of palpitations and weight loss. There was no family history of thyroid disease. She was treated with carbimazole for 6 years before receiving radioactive iodine 15 mCi in May 2022. However, 5 months post RAI, her FT4 remained elevated, ranging from 34.1- 39.1 pmol/L (Normal: 12.3-20.2 pmol/L) with high TSH of 7.12-10.1 mIU/L (Normal: 0.3-3.94 mIU/L). She was restarted on carbimazole and referred to the endocrine unit. On retrospective review, prior to RAI, she had raised FT4 and TSH levels as well. She also reported intermittent headaches for ten years but no visual disturbances and menstrual irregularities. She was clinically euthyroid. Pulse rate was 70/min and regular without beta blocker. She had a small diffuse goitre but no thyroid eye signs, visual field was normal. Thyroid ultrasound showed diffuse thyroid gland enlargement. Additional testing showed no feature of assay interference. Sex-hormone binding globulin was elevated at 190 nmol/L (Normal: 30-90). Prolactin and cortisol were within normal range. MRI of the brain showed a heterogenous sellarsuprasellar mass measuring 2.0 x 2.5 x 2.4 cm. Six months post RAI she had normal FT4 and FT3 on carbimazole 5 mg daily, but TSH was elevated at 65.2 mIU/L. Carbimazole was